Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products
Authors
Keywords
Trastuzumab, Trabectedin, Hairy Cell Leukemia, Diphtheria Toxin, Ixabepilone
Journal
DRUGS
Volume 75, Issue 17, Pages 1993-2016
Publisher
Springer Nature
Online
2015-10-26
DOI
10.1007/s40265-015-0489-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer
- (2016) Rebecca Goldstein et al. Cancer Management and Research
- Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†
- (2015) B. J. Monk et al. ANNALS OF ONCOLOGY
- Using Cytochalasins to Improve Current Chemotherapeutic Approaches
- (2015) Matthew Trendowski Anti-Cancer Agents in Medicinal Chemistry
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CCR 20th Anniversary Commentary: BMS-247550--Microtubule Stabilization as Successful Targeted Therapy
- (2015) N. Pabla et al. CLINICAL CANCER RESEARCH
- The inherent metastasis of leukaemia and its exploitation by sonodynamic therapy
- (2015) Matthew Trendowski CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration
- (2015) Matthew Trendowski et al. INVESTIGATIONAL NEW DRUGS
- Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models
- (2015) Matthew Trendowski et al. INVESTIGATIONAL NEW DRUGS
- Preparation, In Vivo Administration, Dose-Limiting Toxicities, and Antineoplastic Activity of Cytochalasin B
- (2015) Matthew Trendowski et al. Translational Oncology
- Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
- (2014) S. Delaloge et al. ANNALS OF ONCOLOGY
- Ado-trastuzumab Emtansine
- (2014) Patricia A. Corrigan et al. ANNALS OF PHARMACOTHERAPY
- Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach
- (2014) Matthew Trendowski BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Brentuximab vedotin
- (2014) S. M. Ansell BLOOD
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
- (2014) M D’Incalci et al. BRITISH JOURNAL OF CANCER
- HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
- (2014) J C Singh et al. BRITISH JOURNAL OF CANCER
- Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen
- (2014) Raffit Hassan et al. CANCER
- A Reevaluation of CD22 Expression in Human Lung Cancer
- (2014) L. M. Pop et al. CANCER RESEARCH
- Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
- (2014) I. Pastan et al. CANCER RESEARCH
- Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review
- (2014) Laura Polastro et al. Expert Review of Anticancer Therapy
- Trabectedin for the treatment of advanced metastatic soft tissue sarcoma
- (2014) EL Simpson et al. HEALTH TECHNOLOGY ASSESSMENT
- Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
- (2014) J Thompson Coon et al. HEALTH TECHNOLOGY ASSESSMENT
- Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive, Locally Advanced, or Metastatic Breast Cancer
- (2014) Kathy D. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives
- (2014) M. Heiblig et al. LEUKEMIA RESEARCH
- Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
- (2014) Daniele Cretella et al. Molecular Cancer
- Structural basis for the inhibition of the eukaryotic ribosome
- (2014) Nicolas Garreau de Loubresse et al. NATURE
- The development of immunoconjugates for targeted cancer therapy
- (2014) Brandon G. Smaglo et al. Nature Reviews Clinical Oncology
- Trabectedin for advanced soft tissue sarcomas: optimizing use
- (2014) Alison Reid et al. Therapeutics and Clinical Risk Management
- Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
- (2013) R. K. Kelley et al. ANNALS OF ONCOLOGY
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas
- (2013) Jane E. Churpek et al. CANCER
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
- (2013) Hagop Kantarjian et al. CANCER
- A systematic review of dual targeting in HER2-positive breast cancer
- (2013) Iben Kümler et al. CANCER TREATMENT REVIEWS
- Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth
- (2013) Patrick J. Grohar et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Temsirolimus and Thoracic Radiation in Non–Small-Cell Lung Cancer
- (2013) Saiama N. Waqar et al. Clinical Lung Cancer
- Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
- (2013) Baris Boyraz et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer
- (2013) Paul L. McCormack DRUGS
- Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure
- (2013) Karly P. Garnock-Jones DRUGS
- HER2-positive gastric cancer
- (2013) Narikazu Boku Gastric Cancer
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
- (2013) Wei Liao et al. IMMUNITY
- CD30: from basic research to cancer therapy
- (2013) Hiromi Muta et al. IMMUNOLOGIC RESEARCH
- Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia
- (2013) Michael Rytting et al. PEDIATRIC BLOOD & CANCER
- Brentuximab Vedotin: A CD30-Directed Antibody-Cytotoxic Drug Conjugate
- (2013) Ashley M. Newland et al. PHARMACOTHERAPY
- Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents
- (2013) A. E. Prota et al. SCIENCE
- Novel Therapeutic Strategies for Cutaneous T-Cell Lymphoma in Advanced Stages
- (2013) Lillian Kun et al. SEMINARS IN HEMATOLOGY
- Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs
- (2013) Rishil J. Kathawala et al. Chinese Journal of Cancer
- Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
- (2012) Stephanie S Minich ANNALS OF PHARMACOTHERAPY
- Molecular insight in the multifunctional activities of Withaferin A
- (2012) Wim Vanden Berghe et al. BIOCHEMICAL PHARMACOLOGY
- Vimentin DNA methylation predicts survival in breast cancer
- (2012) Jacob Ulirsch et al. BREAST CANCER RESEARCH AND TREATMENT
- Drug-conjugated antibodies for the treatment of cancer
- (2012) John M. Lambert BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Trabectedin has promising antineoplastic activity in high-grade meningioma
- (2012) Matthias Preusser et al. CANCER
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
- (2012) Sandhya Girish et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
- (2012) J. M. Tuscano et al. CANCER RESEARCH
- Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma
- (2012) Michinori Ogura et al. CANCER SCIENCE
- Optimizing radioimmunoconjugate delivery in the treatment of solid tumor
- (2012) Chen-Yu Huang et al. CANCER TREATMENT REVIEWS
- The History of Leukemia Therapy—A Personal Journey
- (2012) Emil J. Freireich Clinical Lymphoma Myeloma & Leukemia
- Eribulin Mesylate (E7389): Review of Efficacy and Tolerability in Breast, Pancreatic, Head and Neck, and Non–Small Cell Lung Cancer
- (2012) Sarah L. Scarpace CLINICAL THERAPEUTICS
- Chemotherapy-Resistant Metastatic Breast Cancer
- (2012) Carrie Marquette et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- The antitumour activities induced by pegylated liposomal cytochalasin D in murine models
- (2012) Feng-ying Huang et al. EUROPEAN JOURNAL OF CANCER
- Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
- (2012) J. A. Barnes et al. HAEMATOLOGICA
- Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways
- (2012) Patrick T. Grogan et al. INVESTIGATIONAL NEW DRUGS
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia
- (2012) Hagop Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
- (2012) David J. Newman et al. JOURNAL OF NATURAL PRODUCTS
- Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development
- (2012) R. J. Kelly et al. MOLECULAR CANCER THERAPEUTICS
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Withaferin A Alters Intermediate Filament Organization, Cell Shape and Behavior
- (2012) Boris Grin et al. PLoS One
- Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway
- (2012) Abbas K. Samadi et al. SURGERY
- Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation
- (2012) Abbas K. Samadi et al. TUMOR BIOLOGY
- Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
- (2012) Frederick Lansigan Cancer Management and Research
- Ixabepilone development across the breast cancer continuum: a paradigm shift
- (2012) N K Ibrahim Cancer Management and Research
- Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
- (2011) M. D. Michaelson et al. ANNALS OF ONCOLOGY
- Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
- (2011) J. S. de Bono et al. ANNALS OF ONCOLOGY
- Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells
- (2011) Xuan Zhang et al. BMC Complementary and Alternative Medicine
- Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors
- (2011) Elaine T. Lam et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
- (2011) Mark Barok et al. CANCER LETTERS
- Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer
- (2011) Javier Cortes et al. CANCER TREATMENT REVIEWS
- Vimentin in cancer and its potential as a molecular target for cancer therapy
- (2011) Arun Satelli et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ 1I
- (2011) George A. Ellestad CHIRALITY
- Ixabepilone: Clinical Role in Metastatic Breast Cancer
- (2011) Neelima Denduluri et al. Clinical Breast Cancer
- Eribulin Mesylate
- (2011) S. Jain et al. CLINICAL CANCER RESEARCH
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Eribulin—A review of preclinical and clinical studies
- (2011) Umang Swami et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group
- (2011) Sylvain Baruchel et al. EUROPEAN JOURNAL OF CANCER
- Omacetaxine mepesuccinate for the treatment of leukemia
- (2011) Theo Daniel Kim et al. EXPERT OPINION ON PHARMACOTHERAPY
- A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer
- (2011) John E. Weldon et al. FEBS Journal
- Inhibition of cell growth and induction of apoptosis in ovarian carcinoma cell lines CaOV3 and SKOV3 by natural withanolide Withaferin A
- (2011) Xuan Zhang et al. GYNECOLOGIC ONCOLOGY
- Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents
- (2011) S. Uboldi et al. INTERNATIONAL JOURNAL OF CANCER
- Corneal Antifibrotic Switch Identified in Genetic and Pharmacological Deficiency of Vimentin
- (2011) Paola Bargagna-Mohan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeted Drug Delivery Using Immunoconjugates
- (2011) Maria Valentina Pasquetto et al. JOURNAL OF IMMUNOTHERAPY
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
- (2011) Bartomeu Massuti et al. LUNG CANCER
- Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
- (2011) Franco Dosio et al. Toxins
- PI3K/AKT/mTOR Pathway in Angiogenesis
- (2011) Jayashree Karar et al. Frontiers in Molecular Neuroscience
- Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
- (2010) Edith A. Perez et al. BREAST CANCER RESEARCH AND TREATMENT
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
- (2010) R C DeConti et al. BRITISH JOURNAL OF CANCER
- Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy
- (2010) Andrew Y. Choo et al. CELL CYCLE
- Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
- (2010) A. S. Wayne et al. CLINICAL CANCER RESEARCH
- Trabectedin
- (2010) Natalie J. Carter et al. DRUGS
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
- (2010) Thomas R. Malek et al. IMMUNITY
- Withaferin A Targets Intermediate Filaments Glial Fibrillary Acidic Protein and Vimentin in a Model of Retinal Gliosis
- (2010) Paola Bargagna-Mohan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2010) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Withaferin A, a Cytotoxic Steroid fromVassobia breviflora, Induces Apoptosis in Human Head and Neck Squamous Cell Carcinoma
- (2010) Abbas K. Samadi et al. JOURNAL OF NATURAL PRODUCTS
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- A Review of Trabectedin (ET-743): A Unique Mechanism of Action
- (2010) Maurizio D'Incalci et al. MOLECULAR CANCER THERAPEUTICS
- Nestin expression in human tumors and tumor cell lines.
- (2010) O. Krupkova_Jr et al. NEOPLASMA
- Keratins in health and cancer: more than mere epithelial cell markers
- (2010) V Karantza ONCOGENE
- In VitroGrowth Inhibitory Effects of Cytochalasins and Derivatives in Cancer Cells
- (2010) Gwendoline Van Goietsenoven et al. PLANTA MEDICA
- Natural products for cancer chemotherapy
- (2010) Arnold L. Demain et al. Microbial Biotechnology
- Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors
- (2009) P. Schmid et al. ANNALS OF ONCOLOGY
- Macromolecular Interaction of Halichondrin B Analogues Eribulin (E7389) and ER-076349 with Tubulin by Analytical Ultracentrifugation
- (2009) P. Holland Alday et al. BIOCHEMISTRY
- Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
- (2009) Jennifer A. Smith et al. BIOCHEMISTRY
- Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation
- (2009) P Chevallier et al. BONE MARROW TRANSPLANTATION
- Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009
- (2009) Alfonso Quintás-Cardama et al. CANCER
- Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
- (2009) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies
- (2009) R. F. Alderson et al. CLINICAL CANCER RESEARCH
- PI3K and mTOR inhibitors—a new generation of targeted anticancer agents
- (2009) Saskia Brachmann et al. CURRENT OPINION IN CELL BIOLOGY
- Denileukin diftitox: a novel immunotoxin
- (2009) George Manoukian et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:
- (2009) Güliz Gürel et al. JOURNAL OF MOLECULAR BIOLOGY
- The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
- (2009) S. C. Alley et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice
- (2009) Y Chen et al. LEUKEMIA
- Ixabepilone: targeting III-tubulin expression in taxane-resistant malignancies
- (2009) C. Dumontet et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of Ixabepilone
- (2009) J. T. Hunt MOLECULAR CANCER THERAPEUTICS
- Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs
- (2009) Edmund I. Graziani NATURAL PRODUCT REPORTS
- Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem
- (2009) Carmen Cuevas et al. NATURAL PRODUCT REPORTS
- Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma
- (2009) Gary R. Hudes et al. SEMINARS IN ONCOLOGY
- Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth
- (2009) James J. Gibbons et al. SEMINARS IN ONCOLOGY
- Discovery and Development of the Epothilones
- (2009) Hans Reichenbach et al. Drugs in research & development
- Critical roles of actin-interacting protein 1 in cytokinesis and chemotactic migration of mammalian cells
- (2008) Asuka Kato et al. BIOCHEMICAL JOURNAL
- A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma
- (2008) Owen A. O’Connor et al. BRITISH JOURNAL OF HAEMATOLOGY
- Preclinical discovery of ixabepilone, a highly active antineoplastic agent
- (2008) Francis Y. F. Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line
- (2008) Fang Liu et al. LIFE SCIENCES
- Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
- (2008) T. Okouneva et al. MOLECULAR CANCER THERAPEUTICS
- Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
- (2008) E. Rivera et al. ONCOLOGIST
- Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
- (2008) A. Y. Choo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More